Litchfield Hills Research Predicts ADIL Q3 Earnings

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) – Equities research analysts at Litchfield Hills Research issued their Q3 2025 earnings per share estimates for shares of Adial Pharmaceuticals in a research report issued on Wednesday, August 20th. Litchfield Hills Research analyst T. O’neill anticipates that the company will earn ($0.08) per share for the quarter. The consensus estimate for Adial Pharmaceuticals’ current full-year earnings is ($1.53) per share. Litchfield Hills Research also issued estimates for Adial Pharmaceuticals’ Q4 2025 earnings at ($0.08) EPS and FY2025 earnings at ($0.52) EPS.

Adial Pharmaceuticals (NASDAQ:ADIL) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.04.

Several other research analysts have also recently issued reports on ADIL. Zacks Research cut shares of Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 20th. Wall Street Zen upgraded shares of Adial Pharmaceuticals to a “sell” rating in a report on Saturday, July 26th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $8.00.

Adial Pharmaceuticals Stock Up 1.0%

Shares of ADIL opened at $0.3838 on Monday. The stock has a 50 day moving average price of $0.38 and a 200 day moving average price of $0.59. The company has a market capitalization of $8.38 million, a price-to-earnings ratio of -0.37 and a beta of 1.00. Adial Pharmaceuticals has a 52-week low of $0.22 and a 52-week high of $1.30.

Institutional Investors Weigh In On Adial Pharmaceuticals

Several hedge funds have recently made changes to their positions in ADIL. Geode Capital Management LLC lifted its position in Adial Pharmaceuticals by 36.0% during the 4th quarter. Geode Capital Management LLC now owns 61,847 shares of the company’s stock worth $62,000 after acquiring an additional 16,381 shares during the period. Citadel Advisors LLC lifted its position in Adial Pharmaceuticals by 63.8% during the 4th quarter. Citadel Advisors LLC now owns 54,508 shares of the company’s stock worth $55,000 after acquiring an additional 21,238 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in shares of Adial Pharmaceuticals during the fourth quarter worth $48,000. Institutional investors and hedge funds own 16.41% of the company’s stock.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.